Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uncontrolled and Persistent Asthma

Conditions

Uncontrolled and Persistent Asthma

Trial Timeline

Jan 1, 2014 → Apr 1, 2014

NCT ID

NCT01989520

About Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E

Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E is a phase 1 stage product being developed by AstraZeneca for Uncontrolled and Persistent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01989520. Target conditions include Uncontrolled and Persistent Asthma.

What happened to similar drugs?

4 of 11 similar drugs in Uncontrolled and Persistent Asthma were approved

Approved (4) Terminated (0) Active (7)

✅Pegloticase + Methotrexate (MTX)AmgenApproved

✅PegloticaseAmgenApproved

✅Pegloticase + Methotrexate (MTX)AmgenApproved

✅Pegloticase with MTXAmgenApproved

🔄HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3

🔄Baxdrostat + PlaceboAstraZenecaPhase 3

🔄TralokinumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01989520	Phase 1	Completed	Jan 1, 2014	Apr 1, 2014	Uncontrolled and Persistent Asthma

Competing Products

17 competing products in Uncontrolled and Persistent Asthma

See all competitors

Product	Company	Stage	Hype Score
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	35
HR17031 injection + insulin glargine	Jiangsu Hengrui Medicine	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 3	44
Tralokinumab	AstraZeneca	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 3	40
Benralizumab	AstraZeneca	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 2	35
Experimental: Tralokinumab	AstraZeneca	Phase 3	40
CIN-107 + Placebo	AstraZeneca	Phase 2	35
Pegloticase + Methotrexate (MTX)	Amgen	Approved	43
Pegloticase	Amgen	Approved	43
Pegloticase + Methotrexate	Amgen	Phase 3	47
Pegloticase + Methotrexate (MTX)	Amgen	Approved	43
Pegloticase with MTX	Amgen	Approved	43
abrocitinib	Pfizer	Pre-clinical	30
REGN5381 + Placebo	Regeneron Pharmaceuticals	Phase 2	27
SAL0140 + SAL0140 placebo	Shenzhen Salubris Pharmaceuticals	Phase 1	36